Morand Piert
Overview
Explore the profile of Morand Piert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kong F, Hu C, Pryma D, Duan F, Matuszak M, Xiao Y, et al.
J Clin Oncol
. 2024 Oct;
42(33):3935-3946.
PMID: 39365957
Purpose: NRG-RTOG0617 demonstrated a detrimental effect of uniform high-dose radiation in stage III non-small cell lung cancer. NRG-RTOG1106/ECOG-ACRIN6697 (ClinicalTrials.gov identifier: NCT01507428), a randomized phase II trial, studied whether midtreatment F-fluorodeoxyglucose...
2.
Edwards D, Schonewolf C, Rice J, Schipper M, Ten Haken R, Matuszak M, et al.
Int J Radiat Oncol Biol Phys
. 2024 Jul;
120(5):1332-1343.
PMID: 38971385
Purpose: Local failure rates after treatment for locally advanced non-small cell lung cancer (NSCLC) remain high. Efforts to improve local control with a uniform dose escalation or dose escalation to...
3.
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
Fendler W, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al.
Eur J Nucl Med Mol Imaging
. 2023 Jan;
50(5):1466-1486.
PMID: 36604326
Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety...
4.
Goldenthal S, Reimers M, Singhal U, Farha M, Mehra R, Piert M, et al.
Urology
. 2022 Apr;
167:171-178.
PMID: 35472327
Objective: To aid in the diagnosis and treatment of patients with metastatic tumor seeding, an exceedingly rare phenomenon following minimally invasive urological surgery, additional case reports are needed. Materials And...
5.
Ferdinandus J, Fendler W, Farolfi A, Washington S, Mohamad O, Pampaloni M, et al.
J Nucl Med
. 2021 Oct;
63(1):76-80.
PMID: 34620731
The European Association of Urology (EAU) prostate cancer guidelines panel recommends risk groups for biochemical recurrence (BCR) of prostate cancer to identify men at high risk of progression or metastatic...
6.
Abghari-Gerst M, Armstrong W, Nguyen K, Calais J, Czernin J, Lin D, et al.
J Nucl Med
. 2021 Jul;
63(4):567-572.
PMID: 34326126
We prospectively investigated the performance of the prostate-specific membrane antigen (PSMA) ligand Ga-PSMA-11 for detecting prostate adenocarcinoma in patients with elevated levels of prostate-specific antigen (PSA) after initial therapy. Ga-PSMA-11...
7.
Morris M, Rowe S, Gorin M, Saperstein L, Pouliot F, Josephson D, et al.
Clin Cancer Res
. 2021 Feb;
27(13):3674-3682.
PMID: 33622706
Purpose: Current FDA-approved imaging modalities are inadequate for localizing prostate cancer biochemical recurrence (BCR). F-DCFPyL is a highly selective, small-molecule prostate-specific membrane antigen-targeted PET radiotracer. CONDOR was a prospective study...
8.
Kim M, Sun Y, Aryal M, Parmar H, Piert M, Rosen B, et al.
Int J Radiat Oncol Biol Phys
. 2021 Feb;
110(3):792-803.
PMID: 33524546
Purpose: We hypothesized that dose-intensified chemoradiation therapy targeting adversely prognostic hypercellular (TV) and hyperperfused (TV) tumor volumes would improve outcomes in patients with glioblastoma. Methods And Materials: This single-arm, phase...
9.
Lebastchi A, Gupta N, DiBianco J, Piert M, Davenport M, Ahdoot M, et al.
Transl Androl Urol
. 2020 Jul;
9(3):1415-1427.
PMID: 32676426
Conventional staging for prostate cancer (PCa) is performed for men diagnosed with unfavorable-intermediate or higher risk disease. Computed tomography (CT) of the abdomen and pelvis and whole body bone scan...
10.
Miller S, Li P, Schipper M, Junck L, Piert M, Lawrence T, et al.
Adv Radiat Oncol
. 2020 Feb;
5(1):53-61.
PMID: 32051890
Purpose: To evaluate whether response assessment of newly diagnosed glioblastoma at 3 months using C-methionine-positron emission tomography (MET-PET) is better associated with patient outcome compared with baseline MET-PET or anatomic...